<p>Recursion Pharmaceuticals, Inc.（納斯達克代碼：RXRX - 獲取免費報告）週一下跌了 6.9%。該公司的股價最低跌至 6.01 美元，最後交易價為 6.14 美元。在午盤交易中，約有 8,113,213 股成交，較日均成交量 25,409,162 股下降了 68%。該股票此前收盤價為 6.59 美元。</p>
<h2>分析師評級變動</h2>
<ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 寵兒嗎？</li>
</ul>
<p>RXRX 已成為多份研究分析師報告的主題。KeyCorp 在 1 月 8 日的報告中將 Recursion Pharmaceuticals 的目標價從 12.00 美元下調至 10.00 美元，並對該股票給予 “增持” 評級。Needham &amp; Company LLC 在 2 月 6 日的研究報告中重申了 “買入” 評級，並將 Recursion Pharmaceuticals 的目標價設定為 11.00 美元。Cowen 在 2 月 28 日的報告中重申了對 Recursion Pharmaceuticals 的 “持有” 評級。最後，Leerink Partners 在 2 月 28 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 7.00 美元下調至 6.00 美元，並對該公司設定了 “市場表現” 評級。三位股票研究分析師對該股票給予了持有評級，兩位給予了買入評級。根據 MarketBeat 的數據，Recursion Pharmaceuticals 的平均評級為 “持有”，平均目標價為 8.25 美元。</p>
<p><strong>查看我們關於 RXRX 的最新報告</strong></p>
<h2>Recursion Pharmaceuticals 價格表現</h2>
<ul>
<li>生物科技處於邊緣：兩隻具有巨大潛力的股票</li>
</ul>
<p>該股票的 50 日移動平均線為 7.64 美元，200 日移動平均線為 7.07 美元。該股票的市值為 24 億美元，市盈率為-4.01，貝塔值為 0.85。該公司的債務與股本比率為 0.04，流動比率為 4.35，速動比率為 4.35。</p>
<p>Recursion Pharmaceuticals（納斯達克代碼：RXRX - 獲取免費報告）最後一次公佈季度財報是在 2 月 28 日。該公司報告每股收益為（0.53 美元），低於分析師一致預期的（0.36 美元），差額為（0.17 美元）。該公司在本季度的收入為 460 萬美元，而分析師預期為 1904 萬美元。Recursion Pharmaceuticals 的淨利潤率為-579.52%，股本回報率為-76.56%。與去年同期相比，Recursion Pharmaceuticals 本季度的收入下降了 57.8%。在去年同期，該公司每股收益為（0.42 美元）。作為一個整體，賣方分析師預測 Recursion Pharmaceuticals, Inc.在當前財年將發佈每股收益-1.57 美元。</p>
<h2>機構投資者對 Recursion Pharmaceuticals 的看法</h2>
<ul>
<li>AI 製藥：通往 AI 驅動藥物投資的兩條路徑</li>
</ul>
<p>幾家對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Decker Retirement Planning Inc.在第四季度購買了價值約 26,000 美元的 Recursion Pharmaceuticals 新頭寸。Private Trust Co. NA 在第四季度獲得了價值 27,000 美元的 Recursion Pharmaceuticals 新股份。GAMMA Investing LLC 在第四季度將其在 Recursion Pharmaceuticals 的持倉提高了 1,979.2%。GAMMA Investing LLC 現在擁有 5,198 股該公司股票，價值 35,000 美元，此前在上個季度增持了 4,948 股。Farther Finance Advisors LLC 在第三季度將其在 Recursion Pharmaceuticals 的持倉提高了 176.9%。Farther Finance Advisors LLC 現在擁有 6,404 股該公司股票，價值 42,000 美元，此前在上個季度增持了 4,091 股。最後，KBC Group NV 在第三季度將其在 Recursion Pharmaceuticals 的持倉提高了 79.9%。KBC Group NV 現在擁有 7,602 股該公司股票，價值 50,000 美元，此前在上個季度增持了 3,377 股。機構投資者和對沖基金持有該公司 89.06% 的股份。</p>
<h2>Recursion Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Recursion Pharmaceuticals, Inc.是一家臨牀階段的生物技術公司，通過整合生物學、化學、自動化、數據科學和工程等技術創新來解碼生物學，以實現藥物發現的工業化。該公司開發的 REC-994 正在進行二期臨牀試驗，以治療腦血管畸形；REC-2282 正在進行二期/三期臨牀試驗，以治療神經纖維瘤病 2 型；REC-4881 正在進行一期 b/二期臨牀試驗，以治療家族性腺瘤性息肉病；REC-3964 正在進行一期臨牀試驗，以治療艱難梭狀芽孢桿菌感染；REC-4881 正在進行二期臨牀試驗，以治療 AXIN1 或 APC 突變癌症。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Recursion Pharmaceuticals 更好</li>
<li>國會股票交易跟蹤</li>
<li>如何在通貨膨脹上升時保護您的投資組合</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>3 只在 2025 年逆勢而上並蓬勃發展的科技股</li>
<li>英國市場假期是什麼？如何投資和交易</li>
<li>儘管面臨挑戰，諾和諾德計劃擊敗 GLP-1 競爭對手</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Recursion Pharmaceuticals 嗎？</h2>
<p>在考慮 Recursion Pharmaceuticals 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Recursion Pharmaceuticals 並不在名單上。</p>
<p>雖然 Recursion Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

RXRX

<p>Recursion Pharmaceuticals（納斯達克代碼：RXRX）股價下跌 6.9%，至 6.14 美元，交易量較平均水平下降 68%。分析師的評級不一，KeyCorp 將其目標價從 12 美元下調至 10 美元，而 Needham 則維持 11 美元的買入評級。該公司報告季度每股虧損 0.53 美元，未能達到預期，營收為 460 萬美元，遠低於預期。機構投資者持有該公司 89.06% 的股份，並且公司正在進行多項針對不同治療的臨牀試驗</p>

<p>Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) dropped 6.9% on Monday . The company traded as low as $6.01 and last traded at $6.14. Approximately 8,113,213 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 25,409,162 shares. The stock had previously closed at $6.59.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.（納斯達克代碼：RXRX - 獲取免費報告）週一下跌了 6.9%。該公司的股價最低跌至 6.01 美元，最後交易價為 6.14 美元。在午盤交易中，約有 8,113,213 股成交，較日均成交量 25,409,162 股下降了 68%。該股票此前收盤價為 6.59 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?</li>
</ul>
<div class="lb-trans"><ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 寵兒嗎？</li>
</ul>
</div><p>RXRX has been the topic of several research analyst reports. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an &#34;overweight&#34; rating on the stock in a report on Wednesday, January 8th. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Cowen restated a &#34;hold&#34; rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a &#34;market perform&#34; rating for the company in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Recursion Pharmaceuticals has an average rating of &#34;Hold&#34; and an average target price of $8.25.</p>
<div class="lb-trans"><p>RXRX 已成為多份研究分析師報告的主題。KeyCorp 在 1 月 8 日的報告中將 Recursion Pharmaceuticals 的目標價從 12.00 美元下調至 10.00 美元，並對該股票給予 “增持” 評級。Needham &amp; Company LLC 在 2 月 6 日的研究報告中重申了 “買入” 評級，並將 Recursion Pharmaceuticals 的目標價設定為 11.00 美元。Cowen 在 2 月 28 日的報告中重申了對 Recursion Pharmaceuticals 的 “持有” 評級。最後，Leerink Partners 在 2 月 28 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 7.00 美元下調至 6.00 美元，並對該公司設定了 “市場表現” 評級。三位股票研究分析師對該股票給予了持有評級，兩位給予了買入評級。根據 MarketBeat 的數據，Recursion Pharmaceuticals 的平均評級為 “持有”，平均目標價為 8.25 美元。</p>
</div><p><strong>Check Out Our Latest Report on RXRX</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 RXRX 的最新報告</strong></p>
</div><h2>Recursion Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 價格表現</h2>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技處於邊緣：兩隻具有巨大潛力的股票</li>
</ul>
</div><p>The stock's 50 day moving average is $7.64 and its two-hundred day moving average is $7.07. The stock has a market capitalization of $2.40 billion, a PE ratio of -4.01 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.</p>
<div class="lb-trans"><p>該股票的 50 日移動平均線為 7.64 美元，200 日移動平均線為 7.07 美元。該股票的市值為 24 億美元，市盈率為-4.01，貝塔值為 0.85。該公司的債務與股本比率為 0.04，流動比率為 4.35，速動比率為 4.35。</p>
</div><p>Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.42) earnings per share. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals（納斯達克代碼：RXRX - 獲取免費報告）最後一次公佈季度財報是在 2 月 28 日。該公司報告每股收益為（0.53 美元），低於分析師一致預期的（0.36 美元），差額為（0.17 美元）。該公司在本季度的收入為 460 萬美元，而分析師預期為 1904 萬美元。Recursion Pharmaceuticals 的淨利潤率為-579.52%，股本回報率為-76.56%。與去年同期相比，Recursion Pharmaceuticals 本季度的收入下降了 57.8%。在去年同期，該公司每股收益為（0.42 美元）。作為一個整體，賣方分析師預測 Recursion Pharmaceuticals, Inc.在當前財年將發佈每股收益-1.57 美元。</p>
</div><h2>Institutional Investors Weigh In On Recursion Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Recursion Pharmaceuticals 的看法</h2>
</div><ul>
<li>AI Pharma: 2 Paths to AI-Powered Drug Investment</li>
</ul>
<div class="lb-trans"><ul>
<li>AI 製藥：通往 AI 驅動藥物投資的兩條路徑</li>
</ul>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in the business. Decker Retirement Planning Inc. purchased a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $26,000. Private Trust Co. NA acquired a new stake in Recursion Pharmaceuticals during the 4th quarter worth $27,000. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after acquiring an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after acquiring an additional 4,091 shares in the last quarter. Finally, KBC Group NV increased its position in shares of Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Decker Retirement Planning Inc.在第四季度購買了價值約 26,000 美元的 Recursion Pharmaceuticals 新頭寸。Private Trust Co. NA 在第四季度獲得了價值 27,000 美元的 Recursion Pharmaceuticals 新股份。GAMMA Investing LLC 在第四季度將其在 Recursion Pharmaceuticals 的持倉提高了 1,979.2%。GAMMA Investing LLC 現在擁有 5,198 股該公司股票，價值 35,000 美元，此前在上個季度增持了 4,948 股。Farther Finance Advisors LLC 在第三季度將其在 Recursion Pharmaceuticals 的持倉提高了 176.9%。Farther Finance Advisors LLC 現在擁有 6,404 股該公司股票，價值 42,000 美元，此前在上個季度增持了 4,091 股。最後，KBC Group NV 在第三季度將其在 Recursion Pharmaceuticals 的持倉提高了 79.9%。KBC Group NV 現在擁有 7,602 股該公司股票，價值 50,000 美元，此前在上個季度增持了 3,377 股。機構投資者和對沖基金持有該公司 89.06% 的股份。</p>
</div><h2>Recursion Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.是一家臨牀階段的生物技術公司，通過整合生物學、化學、自動化、數據科學和工程等技術創新來解碼生物學，以實現藥物發現的工業化。該公司開發的 REC-994 正在進行二期臨牀試驗，以治療腦血管畸形；REC-2282 正在進行二期/三期臨牀試驗，以治療神經纖維瘤病 2 型；REC-4881 正在進行一期 b/二期臨牀試驗，以治療家族性腺瘤性息肉病；REC-3964 正在進行一期臨牀試驗，以治療艱難梭狀芽孢桿菌感染；REC-4881 正在進行二期臨牀試驗，以治療 AXIN1 或 APC 突變癌症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Recursion Pharmaceuticals</li>
<li>Following Congress Stock Trades</li>
<li>How to Protect Your Portfolio When Inflation Is Rising</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>3 Tech Stocks Defying Sector Weakness and Thriving in 2025</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Recursion Pharmaceuticals 更好</li>
<li>國會股票交易跟蹤</li>
<li>如何在通貨膨脹上升時保護您的投資組合</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>3 只在 2025 年逆勢而上並蓬勃發展的科技股</li>
<li>英國市場假期是什麼？如何投資和交易</li>
<li>儘管面臨挑戰，諾和諾德計劃擊敗 GLP-1 競爭對手</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Recursion Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Recursion Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Recursion Pharmaceuticals 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Recursion Pharmaceuticals 並不在名單上。</p>
</div><p>While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Recursion Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Recursion Pharmaceuticals (NASDAQ:RXRX) 股價下跌 6.9% - 你應該賣出嗎？